Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.12 Billion SEK | 43.44% |
| 2022 | 787.67 Million SEK | 243.44% |
| 2021 | 229.34 Million SEK | 26141.08% |
| 2020 | 874 Thousand SEK | -99.53% |
| 2019 | 184.82 Million SEK | 362509.8% |
| 2018 | -51 Thousand SEK | 0.0% |
| 2017 | -51 Thousand SEK | 99.91% |
| 2016 | -56.02 Million SEK | -10.04% |
| 2015 | -50.91 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 281.46 Million SEK | -34.43% |
| 2024 Q2 | 506.33 Million SEK | 79.89% |
| 2023 Q1 | 182.32 Million SEK | -56.71% |
| 2023 FY | 1.12 Billion SEK | 43.44% |
| 2023 Q4 | 429.26 Million SEK | 53.49% |
| 2023 Q3 | 279.67 Million SEK | 9.6% |
| 2023 Q2 | 255.17 Million SEK | 39.95% |
| 2022 Q4 | 421.16 Million SEK | 64.69% |
| 2022 Q2 | 61.66 Million SEK | 25.53% |
| 2022 Q1 | 49.12 Million SEK | 57.54% |
| 2022 FY | 787.67 Million SEK | 243.44% |
| 2022 Q3 | 255.73 Million SEK | 314.74% |
| 2021 Q4 | 31.18 Million SEK | -84.27% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 229.34 Million SEK | 26141.08% |
| 2021 Q3 | 198.16 Million SEK | 0.0% |
| 2020 Q1 | 474 Thousand SEK | -98.98% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 FY | 874 Thousand SEK | -99.53% |
| 2020 Q4 | 400 Thousand SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | 46.58 Million SEK | 0.0% |
| 2019 Q2 | 138.24 Million SEK | 0.0% |
| 2019 Q3 | - SEK | -100.0% |
| 2019 FY | 184.82 Million SEK | 362509.8% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | -51 Thousand SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | -51 Thousand SEK | 99.91% |
| 2016 FY | -56.02 Million SEK | -10.04% |
| 2015 FY | -50.91 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Camurus AB (publ) | 1.58 Billion SEK | 28.515% |
| Mendus AB (publ) | 28.48 Million SEK | -3866.128% |
| Lipum AB (publ) | 53 Thousand SEK | -2131656.604% |
| NextCell Pharma AB | -43.74 Million SEK | 2682.581% |
| Simris Alg AB (publ) | 2 Million SEK | -56194.519% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -9971.333% |
| Active Biotech AB (publ) | -1.67 Million SEK | 67552.597% |
| Amniotics AB (publ) | -1.93 Million SEK | 58640.466% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 267199.527% |
| BioArctic AB (publ) | 346.31 Million SEK | -226.242% |
| Cantargia AB (publ) | -3.45 Million SEK | 32839.235% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -68044.21% |
| CombiGene AB (publ) | -21.29 Million SEK | 5406.691% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 31659.525% |
| Genovis AB (publ.) | 54 Million SEK | -1992.241% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 7532306.667% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 3382.961% |
| Intervacc AB (publ) | -13.79 Million SEK | 8290.742% |
| Kancera AB (publ) | -1.96 Million SEK | 57597.761% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -40150.481% |
| LIDDS AB (publ) | -12.92 Million SEK | 8843.469% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 22179.949% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -11240.269% |
| OncoZenge AB (publ) | 3000.00 SEK | -37660933.333% |
| Saniona AB (publ) | 11.78 Million SEK | -9490.281% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 33126.337% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -3092.695% |
| Xintela AB (publ) | 78 Thousand SEK | -1448401.282% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 12388.786% |
| Ziccum AB (publ) | -23.28 Million SEK | 4951.975% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 803.134% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | -2603.786% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -51941.962% |
| Corline Biomedical AB | 28.38 Million SEK | -3881.082% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 1020.553% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -4112.486% |
| Aptahem AB (publ) | 2.63 Million SEK | -42848.772% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1467212.987% |
| Fluicell AB (publ) | 1.73 Million SEK | -64907.537% |
| Biovica International AB (publ) | 6.87 Million SEK | -16329.126% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 4952.601% |
| AcouSort AB (publ) | 8.38 Million SEK | -13368.006% |
| Abliva AB (publ) | -35.66 Million SEK | 3268.076% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 869.116% |
| 2cureX AB (publ) | -37.48 Million SEK | 3113.927% |
| I-Tech AB | 27.56 Million SEK | -3998.64% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | -1492.41% |
| Cyxone AB (publ) | 2.61 Million SEK | -43171.965% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -33101.029% |
| Biosergen AB | -456 Thousand SEK | 247869.956% |
| Nanologica AB (publ) | -76 Thousand SEK | 1486719.737% |
| SynAct Pharma AB | -778 Thousand SEK | 145322.494% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 585504.663% |
| BioInvent International AB (publ) | 71.46 Million SEK | -1481.046% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | -5584.97% |
| Oncopeptides AB (publ) | 36.29 Million SEK | -3012.568% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -77125.944% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 107805.529% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -35962.273% |